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INTRODUCTION: Venous malformations are the most frequent vascular malformation. Deep venous malformations
are located in subcutaneous tissue or in the muscles. Percutaneous sclerotherapy is the treatment of choice, and the
use of ethanol at low doses has not yet been described.
OBJECTIVE: To analyze the results of treating Deep venous malformations patients with low doses of ethanol.
METHODS: Thirty-nine patients treated between July 1995 and June 2007 were followed up prospectively over a
median period of 18 months. Twenty-nine were female (74.4%) and 10 were male (25.6%), with ages ranging from
11 to 59 years (median of 24 years). All of the lesions affected limbs, and the main symptom reported was pain
(97.4%). Each patient underwent fortnightly alcohol application sessions under local anesthesia on an outpatient
basis. The lesions were classified into three groups according to size using nuclear magnetic resonance imaging:
small, up to 3 cm (4 patients); medium, between 3 and 15 cm (27 patients); and large, greater than 15 cm (8
patients).
RESULTS: The symptoms completely disappeared in 14 patients (35.9%) and improved in 24 (61.5%). The lesion size
reduced to zero in 6 patients (15.4%) and decreased in 32 (82%). The median number of sessions was 7. There were
no complications in 32 patients (82%), while 3 presented local paresthesia (7.7%), 2 superficial trombophlebites
(5.1%), 1 skin ulcer (2.6%), and 1 case of hyperpigmentation (2.6%).
CONCLUSION: Outpatient treatment for Deep venous malformations patients using ethanol at low doses was
effective, with a low complication rate.
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INTRODUCTION
Venous malformations are the most common sympto-
matic vascular malformations.1 They consist of spongy
tangles of veins of varying sizes, formed by venular
capillaries, venules, and veins.2 They may be located in
any portion of the body in a diffusely or delimited form.
The superficial vascular malformations are associated
with skin color modifications, which may present a bluish
color and lead to aesthetic manifestations and, frequently, to
a social phobia.3,4 Deep venous malformations (DVMs) are
located deeply in subcutaneous tissues or in the muscles
and generally cause local pain.2,3
Surgical excision does not produce good results because
of its functional and aesthetic sequelae and because of the
high recurrence rate.5,6 Percutaneous injection of sclerosing
agents into the lesion has become the mainstay of
treatment.7,8,9 Ethanol is considered the most powerful
and effective sclerosing agent,10 but its use at high doses
may cause complications, thus making this a high-risk
treatment.11,12
The use of ethanol at low doses administered in
consecutive sessions on an outpatient basis has not yet
been described in the literature. This may produce good
clinical results with lower risk for patients. The goal of this
study was to analyze the results of treating patients with
DVMs with low doses of ethanol under local anesthesia,
with a median follow-up of 18 months.
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MATERIAL AND METHODS
Thirty-nine patients with DVMs were treated on an
outpatient basis by means of percutaneous sclerosis using
low doses of ethanol under local anesthesia between July
1995 and June 2007 and were followed up prospectively.
Twenty-nine were female (74.4%) and 10 were male (25.6%),
with ages ranging from 11 to 59 years (median of 24 years).
The length of follow-up ranged from six to 72 months, with
a median of 18 months.
The patients’ clinical characteristics are presented in
Table 1:
Most of the lesions affected the lower limbs. The main
symptom reported was pain, and most of the patients had
not undergone any type of previous treatment.
The lesions were classified according to their size. Using
nuclear magnetic resonance imaging (MRI), we measured
them along their longer axis and grouped them into 3
categories: small, for lesions measuring up to 3 cm (4
patients); medium, for lesions between 3 and 15 cm (27
patients); and large, for lesions greater than 15 cm (8
patients).
Each patient underwent fortnightly therapeutic sessions
of ethanol application. The most appropriate puncture site
was chosen by means of palpation of the lesion to locate the
point with the greatest volume (after MRI analysis). The
ethanol application technique consisted of percutaneous
puncture of the lesion13 using a 21 scalpel or a 3067 mm
needle. This was directed perpendicularly to the skin until it
reached the anomalous venous space, which was confirmed
by the presence of blood reflux. Following this, the
radiological contrast medium sodium meglumine ioxaglate
(Hexabrix 320) was injected manually in a slow and gradual
manner. Under fluoroscopic control, the opacification of the
anomalous space was monitored, with quantification of the
conditions and volume of drainage into the venous system.
Approximately 2 ml of 2% lidocaine hydrochloride was then
injected, without vasoconstrictor. Next, the sclerosing agent
was injected and the volume was calculated to be equal to
the contrast used during the angiographic evaluation by
respecting the maximum dose of 1 ml/kg. Immediately
before removing the needle, another small quantity of
anesthetic was injected with the aim of flushing out any
ethanol residue still in the needle. Finally, the needle was
removed from the puncture site and a slightly compressive
dressing was applied for 24 hours. The patient remained
under observation for around 30 minutes and was then
discharged.
The final evaluation of the venous lesions was based on
clinical (milimetric measurement of the circumference at the
site of largest volume of the lesion) and radiological (MRI)
parameters, ascertained before and after treatment. The
clinical evolution following alcohol application, the reduc-
tion in the size of the lesions, the number of alcohol
application sessions, and the complications related to the
procedure were evaluated.
STATISTICAL ANALYSIS
Frequency distribution was used to describe the catego-
rical variables, and central trend and variability measure-
ments were used for the numerical variables. To investigate
the relationship between the results before and after the
embolization treatment, the McNemar test was applied. The
Mann-Whitney U test was used to compare the number of
sessions for variables with 2 categories, and the Kruskal-
Wallis test was used for variables with 3 categories. A
significance level of 5% was used for all of the statistical
tests.
RESULTS
After the treatment, the symptoms completely disap-
peared in 14 patients (35.9%) and improved in 24 (61.5%).
They remained unchanged in only 1 patient (2.6%). The
lesion size reduced to zero in 6 patients (15.4%) and
decreased in 32 (82%). It remained unchanged in only 1
patient (2.6%). The evolution of DVM size compared with
the initial size of the lesion is presented in Table 2:
The treatment was effective, independent of the lesion
size.
The number of sessions held for treatment of DVMs is
presented in Table 3:
The number of sessions ranged from 3 to 34, with a
median of 7. The number was statistically the same
independently the size of the DVM.
Figures 1a (before treatment) and 1b (after treatment)
show a patient with a muscular lesion in his calf:
There were no complications in 32 patients (82%), while 3
presented local paresthesia (7.7%), 2 superficial thromboph-
lebitis (5.1%), 1 skin ulcer (2.6%) and 1 case of hyperpig-
mentation (2.6%). All of the complications were treated
conservatively, with good evolution.
DISCUSSION
DVMs are characterized by venous tumor formation with
soft consistency that can be depressed by palpation, without
any arterial tremor, murmur, or beat involving the
subcutaneous cellular tissue.3 They are present from the
Table 1 - Clinical characteristics.
Lesion location Lower limb 28 (71,8 %)
Upper limb 11 (28,2 %)
Clinical manifestation Pain 38 (97,4 %)
Other symptoms 1 (2,6 %)
Previous treatment None 31 (79,5 %)
Surgery,biopsy or embolization 8 (20,5 %)
Table 2 - Evolution of lesion size.
Group Decrease n (%) Unchanged n (%)
Small 4 (100,0) 0
Medium 26 (96,3) 1 (3,7)
Large 8 (100,0) 0
n = number of patients
Table 3 - Number of sessions (n).
Group Range (n) Median (n) Mean (n) SD p-value
Small 3 - 6 5 4,8 1,5
Medium 3 - 34 7 11,3 9,4 0,1168
Large 4 - 23 12 12,6 6,7
n = number of sessions SD = standard deviation
p - value obtained from Kruskal-Wallis test
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time of birth and present slow growth as the individual
develops. They do not undergo spontaneous involution,
unlike hemangiomas, which present rapid growth followed
by stabilization or spontaneous involution.14
They may be located in any region of the body, but most
of them affect the limbs,3 as seen in the present sample. Pain
is the main complaint, and it is directly related to the size of
the lesion (because of compression of the neighboring
tissue) as well as to inflammatory processes resulting from
phlebitis.
In most cases, DVMs do not cause trophic skin lesions or
cardiovascular manifestations. Occurrences of thromboph-
lebitis are common and usually caused by stagnant blood
flow. If such conditions occur repeatedly, it leads to the
formation of calcifications known as phleboliths, which can
be seen on simple radiographs.2
The diagnosis of venous malformations is primarily
clinical. If there is a suspicion that deep structures may
be involved, especially in extensive lesions, complemen-
tary imaging examinations should be performed.15 The best
imaging examination is magnetic resonance imaging.16 On
T2-weighted or inversion-recovery sequences, DVMs con-
sist of hyperintense channels or areas containing septation.
Small fluid levels may be visible. Phleboliths may be evident
as areas of signal void. Direct percutaneous cannulation of
the malformation with contrast injection typically shows
best the interconnecting spaces and draining veins.12
Ultrasonography may be used to distinguish between
lesions of high and low flow rates and to assist in locating
them. Recently, it has been used as a tool for guiding percu-
taneous punctures during sclerotherapy sessions.17,18
The percutaneous route for treating DVMs began to be
used because it allows direct contact between the sclerosing
agent and the vascular endothelium. Many different
sclerosing agents have been used, including ehtibloc,
sodium tetradecil sulphate, polydocanol, and ethanol.19
Sodium tetradecyl sulphate (sotradecol) and polidocanol
present detergent action that causes endothelial damage by
interfering with the lipids on the cell surface.20,21 However,
the efficacy of these agents decreases in the presence of
greater volume of blood that frequently occurs inside these
anomalous cavities. In the same way as ethanol, these
sclerosing agents cause endothelial lesions resulting in
thrombosis and fibrosis, but there is a great tendency
toward recanalization.10,22 Furthermore, the use of sotrade-
col to treat extensive localized venous anomalies in the
cephalic segment causes significant complications such as
anaphylactic shock and loss of vision.7,23
Ethibloc24 is a highly viscous sclerosing agent with a
poorly understood mechanism of action. The efficacy of the
agent is related to the presence of 60% ethanol in its
composition.9 Ethanol deserves attention because of its
potent fibrosing action, known and controllable side effects,
low cost, and ease of availability.8,25,26 Direct contact
between ethanol and the vascular endothelium promotes
the denaturing of blood proteins, necrosis of the vessel wall,
breakup of erythrocytes, and subsequent thrombosis, which
then leads to fibrosis of the intima, with regression of the
malformation.27
The ethanol dose used during intervention procedures is
strongly correlated with the serum level of ethanol in these
patients. Because of the toxic action of ethanol, occurrences
of side effects are related directly to the quantity of the agent
injected into the organism. Doses greater than 1.0 ml/kg
may lead to respiratory depression, cardiac arrhythmia,
rhabdomyolysis, and hypoglycemia.10,28
The great many studies have described the use of large
volumes of ethanol under general anesthesia. However,
many types of complications have been found, including the
following: immediate thrombosis inside the lesion and
blockage of the venous circulation, thereby leading to severe
edema;29 superficial thrombophlebitis; deep vein thrombo-
sis alone or complicated with pulmonary embolism;9,11
cardiac arrest;10 trophic skin scars or lesions;30 and even
death secondary to cardiovascular collapse.31,32
All patients tolerated the consecutive procedures well,
though there was a little local discomfort, in some cases, at
the end of the sclerosing agent injection. The use of low-
dose ethanol minimizes the occurrence of side effects and
local complications such as thrombophlebitis in the drai-
nage veins. Moreover, with local anesthesia, the patients
were able to return to their activities the day after the
procedure was performed.
A disadvantage in this casuistic was the utilization of
radioscopy during the procedure, although of short dura-
tion. More recently, we have been using ultrasonogra-
phy33,34 during the procedure, which – besides not requiring
ionizing radiation – allows precise localization of the
puncture site and the quantification of the volume of the
sclerosing agent injected.
The number of ethanol sessions was similar for all sizes of
lesions, but the treatment was effective independent of the
lesion size, given that partial or complete reduction of the
lesions occurred in all of the groups. Percutaneous
treatment for DVMs on an outpatient basis was effective
since the symptoms disappeared or improved in 97.4% of
the patients.
CONCLUSION
Outpatient treatment for DVM patients using ethanol at
low doses was effective, with a low complication rate.
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